| Factor Information | |
|---|---|
| Data ID | 1795 |
| Factor | the peak velocity of tricuspid regurgitation, TRV (m/s) |
| Description | The main pulmonary artery diameter and the peak velocity of tricuspid regurgitation were higher in CHD patients with severe PAH than in controls and CHD patients without PAH (P<0.05). |
| Biomarker | NA |
| Classification | E10 (physiological factor - other) |
| Association | |
|---|---|
| Application | diagnosis |
| Objective | we investigated whether ADMA could help specifically identify the disease in a relatively large sample size of CHD patients. |
| p Value | <0.05 |
| Conclusion | The main pulmonary artery diameter and the peak velocity of tricuspid regurgitation were higher in CHD patients with severe PAH than in controls and CHD patients without PAH (P<0.05). |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 390 |
| CHD Type | isolated CHD |
| CHD Subtype | VSD/ASD/PDA |
| Reference | |
|---|---|
| PMID | 25737007 |
| Year | 2015 |
| Title | Asymmetric Dimethyl-L-Arginine is a Biomarker for Disease Stage and Follow-Up of Pulmonary Hypertension Associated with Congenital Heart Disease. |
| Sample | ||
|---|---|---|
| Population | PAH-CHD patients | |
| Source | a single-center prospective observational study | |
| Region | Changsha, China | |
| Method | Plasma ADMA levels were measured by enzyme-linked immunosorbent assay. | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | Group B:CHD with mild-to-moderate PAH)(Treatment) | Group A:CHD without PAH(Control) |
| Number | 20 | 20 |
| Age | 31.36 ± 10.5 years | 34.0 ± 12.7 years |
| Gender (Male: Female) | 3:17 | 4:16 |
| Marker Level | 3.00 ± 1.3 m/s | 2.6 ± 0.5 m/s |
